Stay updated on FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Sign up to get notified when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.

Latest updates to the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page
- Check4 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the previous study content with an error message. The visible area shows the site's generic header and footer, indicating the record is inaccessible.SummaryDifference19%

- Check11 days agoChange DetectedThe page now shows Revision: v3.7.0, replacing the previous Revision: v3.6.6. This update reflects an upgrade to the site's content-management/template system rather than changes to the study details.SummaryDifference0.0%

- Check18 days agoChange DetectedResults for the FLX475 dose-escalation study were posted (2026-09-03), and the page now links the Study Protocol (2022-09-01) and the Statistical Analysis Plan (2023-06-09). The record also documents the results submission history (e.g., Results First Submitted/Posted) and related documents provided by the sponsor.SummaryDifference2%

- Check26 days agoChange DetectedThe page revision tag was updated from v3.6.5 to v3.6.6, representing a minor metadata update to the page version.SummaryDifference0.0%

- Check47 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5, indicating a minor update to the page metadata. This change does not modify the study information or user-facing content.SummaryDifference0.0%

- Check61 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4. This reflects a new version of the page content and its metadata.SummaryDifference0.0%

Stay in the know with updates to FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.